<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008461</url>
  </required_header>
  <id_info>
    <org_study_id>BT_SVT</org_study_id>
    <nct_id>NCT02008461</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have conducted a prospective, double-blind, randomized study to assess the
      comparative safety and efficacy of two different ablation strategies, RFA versus RFA plus
      botulinum toxin injection, in patients with supra-ventricular tachyarrhythmias. Results were
      assessed with the use of an implanted monitoring device (IMD).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of episodes of atrial fibrillation</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serious adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Supra-ventricular Tachyarrhythmias</condition>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mapping and radiofrequency ablation are performed by using standard methods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFA+BT injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mapping and radiofrequency ablation are performed by using standard methods.
Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_label>RFA+BT injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin injection</intervention_name>
    <arm_group_label>RFA+BT injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  atrial flutter, AV nodal re-entry tachycardia, focal atrial tachycardia, WPW syndrome

          -  secondary atrial fibrillation

        Exclusion Criteria:

          -  congestive heart failure

          -  LV ejection fraction &lt; 35%

          -  left atrial diameter &gt; 60 mm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evgeny Pokushalov, MD, PhD</last_name>
    <phone>+79139254858</phone>
    <email>e.pokushalov@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>11528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Pokushalov, MD, PhD</last_name>
      <phone>+79139254858</phone>
      <email>E.Pokushalov@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Evgeny Pokushalov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://meshalkin.ru</url>
    <description>State Research Institute of Circulation Pathology Official Site</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

